Titan Biotech Ltd (TITANBIO) is currently trading at 326.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Titan Biotech Limited manufactures biological peptones, extracts and dehydrated culture media used in clinical diagnostics, vaccine and antibiotic production, food and water testing, tissue culture and academic microbiology, operating primarily from its Bhiwadi, Rajasthan facility and reporting both standalone and consolidated audited financials for FY2026. Revenue and profitability strengthened in FY2026 with consolidated total income of Rs.21,160.05 lakhs versus Rs.16,036.33 lakhs in the prior year, indicating roughly 32% year‑on‑year top‑line growth; consolidated total comprehensive income improved to Rs.2,979.70 lakhs, reflecting expanding margins and improved operating leverage. The company is actively modernizing its manufacturing plant to meet international standards, has introduced sterilised gamma‑irradiated media and other specialized products, and increased financial investments substantially, positioning itself for higher‑value regulated customers in pharma and diagnostic markets. Balance sheet and working capital are sizable for the business: consolidated total assets stood at Rs.21,388.48 lakhs with inventories and trade receivables representing material working capital, while the Board recommended a dividend of Rs.0.50 per equity share and reported an unmodified audit opinion for FY2026.

Over the past 52 weeks, Titan Biotech Ltd has traded between a low of ₹137.12 and a high of ₹444.52. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Titan Biotech Ltd has a market capitalization of approximately 1,682.95. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Titan Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 54.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,682.95 Cr, Titan Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Titan Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Titan Biotech Ltd is 54.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.